Trial Profile
An Open-label Study to Assess the Long-term Safety and Efficacy of ONO/GS-4059 in Subjects With Relapsed/Refractory B-cell Malignancies
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Mar 2022
Price :
$35
*
At a glance
- Drugs Tirabrutinib (Primary)
- Indications Chronic lymphocytic leukaemia; Haematological malignancies
- Focus Adverse reactions
- Sponsors Gilead Sciences
- 22 Jan 2021 Status changed from active, no longer recruiting to completed.
- 17 Nov 2020 Planned End Date changed from 1 Oct 2020 to 1 Jan 2021.
- 17 Nov 2020 Planned primary completion date changed from 1 Oct 2020 to 1 Jan 2021.